

Global Vaccine Market: Focus on Product Type (Next-Generation Vaccine), Route of Administration, Disease Type, 22 Countries Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2028

<https://marketpublishers.com/r/GADD14E78D55EN.html>

Date: November 2018

Pages: 278

Price: US\$ 5,000.00 (Single User License)

ID: GADD14E78D55EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Vaccines protect people against serious and potentially deadly diseases. They produce immunity by injecting components and agents inside the body. They greatly reduce the risk of infection by working with the natural defense of the body to safely develop immunity to a disease. Vaccines are developed based on the type of information of the disease. They are also developed for the control of endemic situation and at the time of outbreak of the disease. Adjuvants are used in the vaccine to improve the efficiency and increase the immune response to the vaccine. Moreover, there are several safety and efficacy issues involved with the vaccines. In order to overcome these problems, next-generation vaccines are developed. Next-generation vaccines are currently in the product pipeline which includes, DNA vaccines, recombinant viral vector vaccines, and individualized vaccines. Individualized vaccines are developed based on the phenotype and genotype immune response of an individual.

The purpose of this study is to gain a holistic view of the global vaccine market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global vaccine market. The market has been segmented into “product”, “disease”, “route of administration”, and “region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial

parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global vaccine market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global vaccine market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of the vaccine market in each region for different cancer types, and the key strategies and developments by the prominent vaccine market stake holders.

The answers to the following key questions can be derived from this report:

What are the major market drivers, challenges, and opportunities in the global vaccine market?

What are the underlying structures resulting in the emerging trends within the vaccine industry?

What were the market values of the leading segments and sub-segments of the global vaccine market in 2017?

How will each segment of the global vaccine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?

What are the influencing factors that may affect the market share of the key players?

How will the industry evolve during the forecast period 2018-2028?

What are the key developmental strategies which are implemented by the key

players to sustain in the competitive market?

What are the key vaccine type in vaccine market? What are the major benefits of each type?

How has the market been segmented on the basis of disease type? Which disease type is dominating the global vaccine market, and what is the reason behind its domination?

What are the market shares of each of the companies in the global vaccine market, and what are their contribution?

Who are the key manufacturers in the global vaccine market, and what are their contributions?

What is the scope of each vaccine type, route of administration, and disease type in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?

What are the key regulatory implications in developed and developing regions for vaccines?

What is the growth potential of vaccine in each region, including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?

Which vaccine type is having the most promising growth and in which disease type?

The key players who have been contributing significantly to the global vaccine market are Merck &Co., Inc., GlaxoSmithKline plc, Abbott Laboratories, Bavarian Nordic, Janssen Pharmaceutical NV, Pfizer, Inc., Sanofi Pasteur SA, and Seqirus (a CSL company), among others.

Contents

EXECUTIVE SUMMARY

1 MARKET OVERVIEW

1.1 Different Types and Generation of Vaccines

1.1.1 First-generation Vaccines

1.1.1.1 Live Attenuated Vaccines

1.1.1.2 Inactivated Vaccines (Killed)

1.1.2 Second-generation Vaccines

1.1.2.1 Subunit and Conjugate Vaccines

1.1.2.2 Toxoid Vaccines

1.1.2.3 Recombinant Vaccines

1.1.3 Third-generation Vaccines

1.1.3.1 DNA Vaccines

1.2 Vaccines in a Historical Perspective

1.3 Assumptions and Limitations for Market Size Calculations

1.4 Global Vaccine Market Scenario

2 MARKET DYNAMICS

2.1 Impact Analysis

2.2 Market Drivers

2.2.1 Increasing Outbreak of Epidemic Diseases

2.2.2 Advancements in Vaccine Technologies and Emergence of Effective Vaccine

Delivery System

2.2.3 Increasing Global Focus on Immunization Program

2.2.4 Use of Adjuvants in Vaccines

2.3 Market Restraints

2.3.1 Safety and Efficacy Related Issues

2.3.2 Longer Timeline for Vaccine Production and High Cost Associated with Development of Vaccine

2.4 Market Opportunities

2.4.1 Development of Personalized Vaccines

2.4.2 Implementation of Artificial Intelligence (AI) and Big Data Analytics to Improve Surveillance Capacity

3 COMPETITIVE INSIGHTS

3.1 Key Strategies and Developments

- 3.1.1 Product Launches and Enhancements
- 3.1.2 Joint Ventures, Partnerships, and Collaborations
- 3.1.3 Mergers and Acquisitions
- 3.1.4 Business Expansions
- 3.1.5 Others

3.2 Market Share Analysis

3.3 Industry Attractiveness

- 3.3.1 Bargaining Power of Suppliers
- 3.3.2 Bargaining Power of Buyer
- 3.3.3 Threat of New Entrants
- 3.3.4 Threat of Substitute Products
- 3.3.5 Intensity of Competitive Rivalry

4 INDUSTRY INSIGHTS

4.1 Introduction

4.2 Regulatory Framework

- 4.2.1 Legal Requirements and Framework for Vaccines in the U.S.
- 4.2.2 Legal Requirements and Framework for Vaccines in the Europe
- 4.2.3 Legal Requirements and Framework for Vaccines in the Asia-Pacific

4.3 Regulatory Scenario

4.4 Product Pipeline Analysis

5 GLOBAL VACCINE MARKET (BY ROUTE OF ADMINISTRATION)

5.1 Intramuscular (IM) Vaccine

5.2 Subcutaneous Vaccine

5.3 Oral Vaccine

5.4 Intravenous (IV) Vaccine

5.5 Other Vaccines

6 GLOBAL VACCINE MARKET (BY TYPE)

6.1 Subunit and Conjugate Vaccine

6.2 Live Attenuated Vaccine

6.3 Inactivated Vaccine

6.4 Recombinant Vaccine

6.5 Toxoid Vaccine

6.6 Next-generation Vaccine

7 GLOBAL VACCINE MARKET (BY DISEASE TYPE)

7.1 Pneumococcal Disease

7.2 Diphtheria, Tetanus, and Pertussis (DTP)

7.3 Influenza

7.4 Cancer

7.5 Human Papilloma Virus (HPV)

7.6 Meningococcal Disease

7.7 Hepatitis

7.8 Measles, Mumps, and Rubella (MMR)

7.9 Rotavirus

7.10 Varicella

7.11 Other Diseases

8 GLOBAL VACCINE MARKET (BY REGION)

8.1 Overview

8.2 North America

8.2.1 The U.S.

8.2.2 Canada

8.3 Europe

8.3.1 Germany

8.3.2 France

8.3.3 The U.K.

8.3.4 Spain

8.3.5 Italy

8.3.6 Switzerland

8.3.7 Rest-of-Europe

8.4 Asia-Pacific

8.4.1 China

8.4.2 India

8.4.3 Japan

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest-of-APAC

8.5 Latin America

- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest-of-Latin America
- 8.6 Middle East and Africa
 - 8.6.1 Gulf Cooperation Council (GCC)
 - 8.6.2 South Africa
 - 8.6.3 Rest-of-Middle East and Africa

9 COMPANY PROFILES

- 9.1 Overview
- 9.2 Abbott Laboratories
 - 9.2.1 Company Overview
 - 9.2.2 Role of Abbott Laboratories in Global Vaccine Market
 - 9.2.3 Financials
 - 9.2.3.1 Key Insights on Financial Health of Company
 - 9.2.4 SWOT Analysis
- 9.3 AstraZeneca plc
 - 9.3.1 Company Overview
 - 9.3.2 Role of AstraZeneca plc in the Vaccine Market
 - 9.3.3 Financials
 - 9.3.3.1 Key Insights on Financial Health of Company
 - 9.3.4 SWOT Analysis
- 9.4 BiondVax Pharmaceuticals Ltd.
 - 9.4.1 Company Overview
 - 9.4.2 Role of BiondVax Pharmaceuticals Ltd. in the Vaccine Market
 - 9.4.3 Financials
 - 9.4.3.1 Key Insights on the Financial Health of the Company
 - 9.4.4 SWOT Analysis
- 9.5 Bavarian Nordic
 - 9.5.1 Company Overview
 - 9.5.2 Role of Bavarian Nordic in Global Vaccine Market
 - 9.5.3 Financials
 - 9.5.3.1 Key Insights on Financial Health of Company
 - 9.5.4 SWOT Analysis
- 9.6 CSL Limited
 - 9.6.1 Company Overview
 - 9.6.2 Role of CSL Limited in the Vaccine Market
 - 9.6.3 Financials

- 9.6.3.1 Key Insights on the Financial Health of the Company
- 9.6.4 SWOT Analysis
- 9.7 Daiichi Sankyo Company, Limited
 - 9.7.1 Company Overview
 - 9.7.2 Role of Daiichi Sankyo Company, Limited in Global Vaccine Market
 - 9.7.3 Financials
 - 9.7.3.1 Key Insights on Financial Health of Company
 - 9.7.4 SWOT Analysis
- 9.8 Emergent BioSolutions Inc.
 - 9.8.1 Company Overview
 - 9.8.2 Role of Emergent BioSolutions Inc. in the Vaccine Market
 - 9.8.3 Financials
 - 9.8.3.1 Key Insights on Financial Health of Company
 - 9.8.4 SWOT Analysis
- 9.9 GlaxoSmithKline plc
 - 9.9.1 Company Overview
 - 9.9.2 Role of GlaxoSmithKline plc in Global Vaccine Market
 - 9.9.3 Financials
 - 9.9.3.1 Key Insights on Financial Health of Company
 - 9.9.4 SWOT Analysis
- 9.10 Inovio Pharmaceuticals Inc.
 - 9.10.1 Company Overview
 - 9.10.2 Role of Inovio pharmaceuticals Inc. in the Global vaccine market
 - 9.10.3 Financials
 - 9.10.3.1 Key Insights on the Financial Health of the Company
 - 9.10.4 SWOT Analysis
- 9.11 Johnson & Johnson
 - 9.11.1 Company Overview
 - 9.11.2 Role of Johnson & Johnson in the Global Vaccine Market
 - 9.11.3 Financials
 - 9.11.3.1 Key Insights on the Financial Health of the Company
 - 9.11.4 SWOT Analysis
- 9.12 Merck & Company Inc.
 - 9.12.1 Company Overview
 - 9.12.2 Role of Merck& Co., Inc. in the Global vaccine market
 - 9.12.3 Financials
 - 9.12.3.1 Key Insights on Financial Health of Company
 - 9.12.4 SWOT Analysis
- 9.13 Madison Vaccines Incorporated

- 9.13.1 Company Overview
- 9.13.2 Role of Madison Vaccines Incorporated in the Global Vaccine Market
- 9.13.3 SWOT Analysis
- 9.14 Pfizer, Inc.
 - 9.14.1 Company Overview
 - 9.14.2 Role of Pfizer, Inc. Incorporated in the Global vaccine market
 - 9.14.3 Financials
 - 9.14.3.1 Key Insights on the Financial Health of the Company
 - 9.14.4 SWOT Analysis
- 9.15 Sanofi S.A.
 - 9.15.1 Company Overview
 - 9.15.2 Role of Sanofi S.A. in the Vaccine Market
 - 9.15.3 Financials
 - 9.15.3.1 Key Insights on the Financial Health of the Company
 - 9.15.4 SWOT Analysis
- 9.16 Sinovac Biotech Ltd.
 - 9.16.1 Company Overview
 - 9.16.2 Role of Sinovac Biotech Ltd. in the Global vaccine market
 - 9.16.3 Financials
 - 9.16.3.1 Key Insights on the Financial Health of the Company
 - 9.16.4 SWOT Analysis
- 9.17 Valneva SE
 - 9.17.1 Company Overview
 - 9.17.2 Role of Valneva SE in the Global vaccine market
 - 9.17.3 Financials
 - 9.17.3.1 Key Insights on Financial Health of Company
 - 9.17.4 SWOT Analysis
- 9.18 VBI Vaccine Inc.
 - 9.18.1 Company Overview
 - 9.18.2 Role of VBI Vaccine Inc. in the Global Vaccine Market
 - 9.18.3 Financials
 - 9.18.3.1 Key Insights on Financial Health of Company
 - 9.18.4 SWOT Analysis

10 RESEARCH SCOPE AND METHODOLOGY

- 10.1 Report Scope
- 10.2 Global Vaccine Market: Research Methodology

List Of Tables

LIST OF TABLES

Table 2.1 Impact Analysis

Table 2.2 Vaccination Coverage (by Vaccine and WHO Region) - Worldwide, 2016

Table 3.1 Number of Mergers and Acquisitions (by Each Company), January 2015-September 2018

Table 3.2 Number of Business Expansion (by Each Company), January 2015-September 2018

Table 4.1 The European Medicines Agency's Scientific Guidelines on Vaccines

Table 4.2 Regulatory Scenario Across the World

Table 7.1 Global Vaccine Market (by Disease Type), 2017-2028

Table 8.1 North America Vaccine Market (by Disease Type), 2017-2028

Table 8.2 Europe Vaccine Market (by Disease Type), 2017-2028 (\$Billion)

Table 8.3 APAC Vaccine Market (by Disease Type), 2017-2028 (\$Billion)

Table 8.4 Latin America Vaccine Market (by Disease Type), 2017-2028 (\$Billion)

Table 8.5 Middle East and Africa Vaccine Market (by Disease Type), 2017-2028 (\$Billion)

List Of Figures

LIST OF FIGURES

- Figure 1 Global Vaccine Market Structure
- Figure 2 Impact of Market Drivers and Market Restraints, 2017 and 2028
- Figure 3 Global Vaccine Market Snapshot
- Figure 4 Dominating Segments of Global Vaccine Market, 2017 and 2028
- Figure 5 Global Vaccine Market (by Vaccine type), 2017 and 2028
- Figure 6 Global Vaccine Market (by Route of Administration), 2017 and 2028
- Figure 7 Global Vaccine Market (by Region), 2017 and 2028
- Figure 8 Global Vaccine Market (by Region), 2017 and 2028
- Figure 9 Market Statistics
- Figure 10 Market Share Analysis: Global Vaccine Market, 2017
- Figure 11 Opportunity Map Analysis of Next-generation Vaccines
- Figure 1.1 Classification of Global Vaccine Market
- Figure 1.2 Different Types and Generation of Vaccines
- Figure 1.3 Components of a Vaccine
- Figure 1.4 Evolution of Vaccines against Diseases
- Figure 1.5 Global Vaccine Market, 2017-2028
- Figure 2.1 Market Dynamics of Global Vaccine Market
- Figure 3.1 Competitive Landscape, January 2015-September 2018
- Figure 3.2 Share of Key Developments and Strategies, January 2015-September 2018
- Figure 3.3 Product Launches Share (by Companies), January 2015- September 2018
- Figure 3.4 Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-September 2018
- Figure 3.5 Others Share (by Companies), January 2015-September 2018
- Figure 3.6 Market Share Analysis: Global Vaccine Market, 2016 and 2017
- Figure 3.7 Porter's Five Forces Analysis
- Figure 3.8 Bargaining Power of Suppliers: Overall Impact, 2015-2028
- Figure 3.9 Bargaining Power of Buyers: Overall Impact, 2015-2028
- Figure 3.10 Threat of New Entrant: Overall Impact, 2015-2028
- Figure 3.11 Threat of Substitute Products: Overall Impact, 2014-2028
- Figure 3.12 Intensity of Competitive Rivalry: Overall Impact, 2015-2028
- Figure 4.1 Industry Insights, January 2015-May 2018
- Figure 4.2 Regulatory Pathway from Preclinical to the Marketing Authorization
- Figure 4.3 Pipeline Analysis
- Figure 4.4 Pipeline Analysis According to Clinical Trial Phases
- Figure 5.1 Global Vaccine Market (by Route of Administration)

- Figure 5.2 Global Vaccine Market (by Route of Administration), 2017-2028
- Figure 5.3 Global Vaccine Market (by Intramuscular), 2017-2028
- Figure 5.4 Global Vaccine Market (by Subcutaneous), 2017-2028
- Figure 5.5 Global Vaccine Market (by Oral Vaccine), 2017-2028
- Figure 5.6 Global Vaccine Market (by Intravenous vaccine), 2017-2028
- Figure 5.7 Global Vaccine Market (by Others), 2017-2028
- Figure 6.1 Global Vaccine Market (by Type)
- Figure 6.2 Global Vaccine Market (by Type), 2017-2028
- Figure 6.3 Global Vaccine Market (by Subunit and Conjugate), 2017-2028
- Figure 6.4 Global Vaccine Market (by Live Attenuated), 2017-2028
- Figure 6.5 Global Vaccine Market (by Inactivated), 2017-2028
- Figure 6.6 Global Vaccine Market (by Recombinant), 2017-2028
- Figure 6.7 Global Vaccine Market (by Toxoid), 2017-2028
- Figure 6.8 Global Vaccine Market (by Next-Generation), 2021-2028
- Figure 7.1 Global Vaccine Market (by Disease Type)
- Figure 7.2 Global Vaccine Market (by Pneumococcal Disease), 2017-2028
- Figure 7.3 Global Pneumococcal Disease Vaccine Market (by Region), 2017-2028
- Figure 7.4 Global Vaccine Market (by DTP), 2017-2018
- Figure 7.5 Global DTP Disease Vaccine Market (by Region), 2017-2028
- Figure 7.6 Global Vaccine Market (by Influenza), 2017-2028
- Figure 7.7 Global Influenza Vaccine Market (by Region), 2017-2028
- Figure 7.8 Global Vaccine Market (by Cancer), 2017-2028
- Figure 7.9 Global Cancer Vaccine Market (by Region), 2017-2028
- Figure 7.10 Global Vaccine Market (by HPV), 2017-2028
- Figure 7.11 Global HPV Vaccine Market (by Region), 2017-2028
- Figure 7.12 Global Vaccine Market (by Meningococcal Disease), 2017-2028
- Figure 7.13 Global Meningococcal Disease Vaccine Market (by Region), 2017-2028
- Figure 7.14 Global Vaccine Market (by Hepatitis), 2017-2028
- Figure 7.15 Global Hepatitis Disease Vaccine Market (by Region), 2017-2028
- Figure 7.16 Global Vaccine Market (by MMR), 2017-2028
- Figure 7.17 Global MMR Vaccine Market (by Region), 2017-2028
- Figure 7.18 Global Vaccine Market (by Rotavirus), 2017-2028
- Figure 7.19 Global Rotavirus Vaccine Market (by Region), 2017-2028
- Figure 7.20 Global Vaccine Market (by Varicella), 2017-2028
- Figure 7.21 Global Varicella Vaccine Market (by Region), 2017-2028
- Figure 7.22 Global Vaccine Market (by Others), 2017-2028
- Figure 8.1 Global Vaccine Market (by Region), 2017 and 2028
- Figure 8.2 Global Vaccine Market (by Vaccine Market), 2017-2028
- Figure 8.3 North America Vaccine Market, 2017-2028

- Figure 8.4 North America: Market Dynamics
- Figure 8.5 North America Vaccine Market (by Country), 2017-2028
- Figure 8.6 North America Vaccine Market (by Vaccine Type), 2017-2028
- Figure 8.7 North America Vaccine Market (by Route of Administration), 2017-2028
- Figure 8.8 U.S. Vaccine Market, 2017-2028
- Figure 8.9 Canada Vaccine Market, 2017-2028
- Figure 8.10 Europe Vaccine Market, 2017-2028
- Figure 8.11 Europe: Market Dynamics
- Figure 8.12 Europe Vaccine Market (by Country), 2017-2028
- Figure 8.13 Europe Vaccine Market (by Vaccine Type), 2017-2028
- Figure 8.14 Europe Vaccine Market (by Route of Administration), 2017-2028
- Figure 8.15 Germany Vaccine Market, 2017-2028
- Figure 8.16 France Vaccine Market, 2017-2028
- Figure 8.17 U.K. Vaccine Market, 2017-2028
- Figure 8.18 Spain Vaccine Market, 2017-2028
- Figure 8.19 Italy Vaccine Market, 2017-2028
- Figure 8.20 Switzerland Vaccine Market, 2017-2028
- Figure 8.21 Rest-of-Europe Vaccine Market, 2017-2028
- Figure 8.22 APAC Vaccine Market, 2017-2028
- Figure 8.23 APAC: Market Dynamics
- Figure 8.24 APAC Vaccine Market (by Country), 2017-2028
- Figure 8.25 APAC Vaccine Market (by Vaccine Type), 2017-2028
- Figure 8.26 APAC Vaccine Market (by Route of Administration), 2017-2028
- Figure 8.27 China Vaccine Market, 2017-2028
- Figure 8.28 India Vaccine Market, 2017-2028
- Figure 8.29 Japan Vaccine Market, 2017-2028
- Figure 8.30 Australia Vaccine Market, 2017-2028
- Figure 8.31 South Korea Vaccine Market, 2017-2028
- Figure 8.32 Rest-of-APAC Vaccine Market, 2017-2028
- Figure 8.33 Latin America Vaccine Market, 2017-2028
- Figure 8.34 Latin America: Market Dynamics
- Figure 8.35 Latin America Vaccine Market (by Country), 2017-2028
- Figure 8.36 Latin America Vaccine Market (by Vaccine Type), 2017-2028
- Figure 8.37 Latin America Vaccine Market (by Route of Administration), 2017-2028
- Figure 8.38 Brazil Vaccine Market, 2017-2028
- Figure 8.39 Mexico Vaccine Market, 2017-2028
- Figure 8.40 Rest-of-Latin America Vaccine Market, 2017-2028
- Figure 8.41 Middle East and Africa Vaccine Market, 2017-2028
- Figure 8.42 Middle East and Africa: Market Dynamics

- Figure 8.43 Middle East and Africa Vaccine Market (by Country), 2017-2028
- Figure 8.44 Middle East and Africa Vaccine Market (by Vaccine Type), 2017-2028
- Figure 8.45 Middle East and Africa Vaccine Market (by Route of Administration), 2017-2028
- Figure 8.46 GCC Vaccine Market, 2017-2028
- Figure 8.47 South Africa Vaccine Market, 2017-2028
- Figure 8.48 Rest-of- Middle East and Africa Vaccine Market, 2017-2028
- Figure 9.1 Share of Key Company Profiled
- Figure 9.2 Abbott India Ltd. (Subsidiary of Abbott Laboratories): Product Offerings for Global Vaccine Market
- Figure 9.3 Abbott Laboratories: Overall Financials, 2015-2017
- Figure 9.4 Abbott Laboratories: Revenue (by Business Segment), 2015-2017
- Figure 9.5 Abbott Laboratories: Revenue (by Region), 2015-2017
- Figure 9.6 Abbott Laboratories: R&D Expense, 2015-2017
- Figure 9.7 Abbott Laboratories: Revenue Forecast, 2015-2020
- Figure 9.8 Abbott Laboratories: SWOT Analysis
- Figure 9.9 AstraZeneca plc: Product Offerings for Global Vaccine Market
- Figure 9.10 AstraZeneca plc: Overall Financials, 2015-2017
- Figure 9.11 AstraZeneca plc: Revenue (by Region), 2015-2017
- Figure 9.12 AstraZeneca plc: R&D Expense, 2015-2017
- Figure 9.13 AstraZeneca PLC: SWOT Analysis
- Figure 9.14 BiondVax Pharmaceuticals Ltd.: Overall Financials, 2015-2017
- Figure 9.15 BiondVax Pharmaceuticals Ltd.: R&D Expense, 2015-2017
- Figure 9.16 BiondVax Pharmaceuticals Ltd.: SWOT Analysis
- Figure 9.17 Bavarian Nordic: Overall Financials, 2015-2017
- Figure 9.18 Bavarian Nordic: Revenue (by Region), 2015-2017
- Figure 9.19 Bavarian Nordic: R&D Expense, 2015-2017
- Figure 9.20 Bavarian Nordic: Revenue Forecast, 2015-2020
- Figure 9.21 Bavarian Nordic: SWOT Analysis
- Figure 9.22 CSL Limited: Product Offerings for Global Vaccine Market
- Figure 9.23 CSL Limited: Overall Financials, 2015-2017
- Figure 9.24 CSL Limited: Revenue (by Business Segment), 2015-2017
- Figure 9.25 CSL Limited: Revenue (by Region), 2015-2017
- Figure 9.26 CSL Limited: R&D Expense, 2015-2017
- Figure 9.27 CSL Limited: Revenue Forecast, 2015-2020
- Figure 9.28 CSL Limited: SWOT Analysis
- Figure 9.29 Daiichi Sankyo Company, Limited: Product Offerings for Global Vaccine Market
- Figure 9.30 Daiichi Sankyo Company, Limited: Overall Financials, 2015-2017

Figure 9.31 Daiichi Sankyo Company, Limited: Revenue (by Business Segment), 2015-2017

Figure 9.32 Daiichi Sankyo Company, Limited: Revenue (by Region), 2015-2017

Figure 9.33 Daiichi Sankyo Company, Limited: R&D Expense, 2015-2017

Figure 9.34 Daiichi Sankyo Company, Limited: Revenue Forecast, 2015-2020

Figure 9.35 Daiichi Sankyo Company, Limited: SWOT Analysis

Figure 9.36 Emergent BioSolutions Inc.: Product Offerings for Global Vaccine Market

Figure 9.37 Emergent BioSolutions Inc.: Overall Financials, 2015-2017

Figure 9.38 Emergent BioSolutions Inc.: Revenue (by Region), 2015-2017

Figure 9.39 Emergent BioSolutions Inc.: R&D Expense, 2015-2017

Figure 9.40 Emergent BioSolution Inc.: Revenue Forecast, 2015-2020

Figure 9.41 Emergent BioSolutions Inc.: SWOT Analysis

Figure 9.42 GlaxoSmithKline plc: Product Offerings for Global Vaccine Market

Figure 9.43 GlaxoSmithKline plc: Overall Financials, 2015-2017

Figure 9.44 GlaxoSmithKline plc: Revenue (by Business Segment), 2015-2017

Figure 9.45 GlaxoSmithKline plc: Revenue (by Region), 2015-2017

Figure 9.46 GlaxoSmithKline plc: R&D Expense, 2015-2017

Figure 9.47 GlaxoSmithKline plc: Revenue Forecast, 2015-2020

Figure 9.48 GlaxoSmithKline plc: SWOT Analysis

Figure 9.49 Product Offerings

Figure 9.50 Inovio Pharmaceuticals Inc.: Overall Financials, 2015-2017

Figure 9.51 Inovio Pharmaceuticals Inc.: R&D Expense, 2015-2017

Figure 9.52 Inovio pharmaceuticals Inc.: Revenue Forecast, 2015-2020

Figure 9.53 Inovio Pharmaceutical Inc.: SWOT Analysis

Figure 9.54 Johnson & Johnson: Product Offerings for Global Vaccine Market

Figure 9.55 Johnson & Johnson: Overall Financials, 2015-2017

Figure 9.56 Johnson & Johnson: Revenue (by Business Segment), 2015-2017

Figure 9.57 Johnson & Johnson: Revenue (by Region), 2015-2017

Figure 9.58 Johnson & Johnson: R&D Expense, 2015-2017

Figure 9.59 Johnson & Johnson: Revenue Forecast, 2015-2020

Figure 9.60 Johnson & Johnson: SWOT Analysis

Figure 9.61 Merck & Co. Inc.: Product Offerings for Global Vaccine Market

Figure 9.62 Merck & Co: Overall Financials, 2015-2017

Figure 9.63 Merck & Co. Inc.: Revenue (by Business Segment), 2015-2017

Figure 9.64 Merck & Co. Inc.: Revenue (by Region), 2015-2017

Figure 9.65 Merck & Co. Inc.: R&D Expense, 2015-2017

Figure 9.66 Merck & Co. Inc.: Revenue Forecast, 2015-2020

Figure 9.67 Merck & Co. Inc.: SWOT Analysis

Figure 9.68 Madison Vaccines Incorporated: SWOT Analysis

- Figure 9.69 Pfizer, Inc.: Product Offerings for Global Vaccine Market
- Figure 9.70 Pfizer, Inc.: Overall Financials, 2015-2017
- Figure 9.71 Pfizer, Inc.: Revenue (by Business Segment) 2015-2017
- Figure 9.72 Pfizer, Inc.: Revenue (by Region) 2015- 2017
- Figure 9.73 Pfizer, Inc.: R&D Expense, 2015-2017
- Figure 9.74 Pfizer, Inc.: Revenue Forecast, 2015-2020
- Figure 9.75 Pfizer, Inc.: SWOT Analysis
- Figure 9.76 Sanofi S.A.: Product Offerings for Global Vaccine Market
- Figure 9.77 Pipeline Products
- Figure 9.78 Sanofi S.A.: Overall Financials, 2015-2017
- Figure 9.79 Sanofi S.A.: Revenue (by Business Segment), 2015-2017
- Figure 9.80 Sanofi S.A.: Revenue (by Region), 2015-2017
- Figure 9.81 Sanofi S.A.: R&D Expense, 2015-2017
- Figure 9.82 Sanofi S.A.: Revenue Forecast, 2015-2020
- Figure 9.83 Sanofi S.A.: SWOT Analysis
- Figure 9.84 Sinovac Biotech Ltd.: Product Offerings for Global Vaccine Market
- Figure 9.85 Sinovac Biotech Ltd.: Overall Financials, 2015-2017
- Figure 9.86 Sinovac: Revenue (by Region), 2015-2017
- Figure 9.87 Sinovac Biotech Ltd.: R&D Expense, 2015-2017
- Figure 9.88 Sinovac Biotech Ltd.: Revenue Forecast, 2015-2020
- Figure 9.89 Sinovac Biotech Ltd.: SWOT Analysis
- Figure 9.90 Valneva SE: Product Offerings for Global Vaccine Market
- Figure 9.91 Valneva SE.: Overall Financials, 2015-2017
- Figure 9.92 Valneva SE: Revenue (by Business Segment), 2015-2017
- Figure 9.93 Valneva SE: Revenue (by Region), 2015 & 2017
- Figure 9.94 Valneva SE: R&D Expense, 2015-2017
- Figure 9.95 Valneva SE: Revenue Forecast, 2015-2020
- Figure 9.96 Valneva SE.: SWOT Analysis
- Figure 9.97 VBI Vaccine Inc.: Product Offerings for Global Vaccine Market
- Figure 9.98 VBI Vaccine Inc.: Overall Financials, 2015-2017
- Figure 9.99 VBI Vaccine Inc. Revenue (by Region) 2015-2017
- Figure 9.10 0 VBI Vaccine Inc.: R&D Expense, 2015-2017
- Figure 9.10 1 VBI Vaccine Inc.: SWOT Analysis
- Figure 10.1 Global Vaccine Market: Market Segmentation
- Figure 10.2 Global Vaccine Market Segmentation
- Figure 10.3 Primary Research
- Figure 10.4 Secondary Research
- Figure 10.5 Data Triangulation
- Figure 10.6 Top-down Approach (Segment-wise Analysis)

Figure 10.7 Bottom-up Approach (Segment-wise Analysis)

Figure 10.8 Assumptions and Limitations

Figure 10.9 Considered Factors for Data Prediction and Modelling

I would like to order

Product name: Global Vaccine Market: Focus on Product Type (Next-Generation Vaccine), Route of Administration, Disease Type, 22 Countries Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2028

Product link: <https://marketpublishers.com/r/GADD14E78D55EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GADD14E78D55EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970